1. Nomograms for predicting survival outcomes in intensity‐modulated radiotherapy era of nasopharyngeal carcinoma: A study based on <scp>Epstein</scp> – <scp>Barr</scp> virus <scp>DNA</scp> biological responses
- Author
-
Jiangfang Tian, Arthur Shou, Mei Li, Jinbing Zhu, Lei Zeng, Guangjun Li, Yiping Li, Kaixuan Yang, and Wenji Xie
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Epstein-Barr virus DNA ,Induction chemotherapy ,Nomogram ,medicine.disease ,Confidence interval ,Radiation therapy ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Otorhinolaryngology ,Nasopharyngeal carcinoma ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Stage (cooking) ,business - Abstract
Background Treatment of nasopharyngeal carcinoma (NPC) is evolving toward Intensity-modulated radiotherapy (IMRT) era, which requires patient-specific reestimation of survival outcomes in modern health care. Methods A total of 488 detectable pre-treatment Epstein-Barr virus (EBV) DNA patients (stage II-IVa) treated with induction chemotherapy (IC) and IMRT were examined (training set, n = 325; validation set, n = 163). Results Concurrent chemotherapy (CC) was still an independent prognosticator for overall survival (OS) and progression-free survival (PFS). Both nomograms included age, T classification, N classification, post-IC EBV DNA, and CC. Predictions correlated well with observed 3-/5-year OS and PFS. The concordance index was 0.776 (95% confidence interval (CI) 0.69-0.86) for OS and 0.742 (95% CI 0.65-0.83) for PFS in the validation cohort. The nomograms can successfully classify patients into low- and high-risk groups. Conclusion The validated nomograms provided useful prediction of OS and PFS for detectable pre-treatment EBV DNA patients with NPC in IMRT era.
- Published
- 2021
- Full Text
- View/download PDF